Tetra Therapeutics’ Shionogi deal builds resources of large pharmaceutical company
This is an article about portfolio company, Tetra Therapeutics.
After years of raising millions in capital and federal grant funding for Tetra Therapeutics Inc. — which was developing a new drug that could potentially treat Alzheimer’s disease and a form of autism — Mark Gurney in 2020 finally found the big money he needed to get to the end.
The Grand Rapids-based Tetra Therapeutics last spring sold to Japanese pharmaceutical company Shionogi & Co. Ltd. in a deal that could reach $500 million. Under the agreement, Shionogi & Co. acquired Tetra and its portfolio of drug compounds for treating Alzheimer’s disease, Fragile X syndrome, and other brain disorders associated with cognitive or memory conditions
View source version on mibiz.com: https://mibiz.com/sections/health-care/tetra-therapeutics-shionogi-deal-builds-resources-of-large-pharmaceutical-company